Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Trulicity® (dulaglutide): Missed Dose Pharmacokinetics
If a dose of dulaglutide is missed and there are at least 3 days until the next scheduled dose, it should be administered as soon as possible.
If a dose is missed, it should be administered as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose.1
If less than 3 days (72 hours) remain before the next scheduled dose, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day.1
In each case, patients can then resume their regular once weekly dosing schedule.1
The day of weekly administration can be changed if necessary, as long as the last dose was administered 3 or more days (72 hours) before.1
Figure 1. Effect of Missed 1.5 mg Once-Weekly Doses on Dulaglutide Pharmacokinetics at Steady State3
2. Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625-634. http://rd.springer.com/article/10.1007%2Fs40262-015-0338-3
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 06 January 2020